DNLI Q4 2021 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$13M-96.1% YoY

Gross Profit

$13M100.0% margin

Operating Income

-$77M-616.3% margin

Net Income

-$75M-601.4% margin

EPS (Diluted)

$-0.62

QoQ Revenue Growth

+136.8%

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$69M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$442M

Stockholders' Equity

$962M

Cash & Equivalents

$293M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$317M	-96.1%
Gross Profit	$13M	$317M	-96.1%
Operating Income	-$77M	$244M	-131.6%
Net Income	-$75M	$245M	-130.7%